Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? / Andersen, Emilie S.; Lund, A.; Bagger, J. I.; Andreasen, C; Grøndahl, MF; Deacon, Carolyn F.; Hartmann, Bolette; Holst, Jens Juul; Knop, Filip Krag; Lauritsen, Tina Vilsbøll.

I: Diabetes, Obesity and Metabolism, Bind 20, Nr. 8, 08.2018, s. 1937-1943.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Andersen, ES, Lund, A, Bagger, JI, Andreasen, C, Grøndahl, MF, Deacon, CF, Hartmann, B, Holst, JJ, Knop, FK & Lauritsen, TV 2018, 'Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?', Diabetes, Obesity and Metabolism, bind 20, nr. 8, s. 1937-1943. https://doi.org/10.1111/dom.13321

APA

Andersen, E. S., Lund, A., Bagger, J. I., Andreasen, C., Grøndahl, MF., Deacon, C. F., ... Lauritsen, T. V. (2018). Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? Diabetes, Obesity and Metabolism, 20(8), 1937-1943. https://doi.org/10.1111/dom.13321

Vancouver

Andersen ES, Lund A, Bagger JI, Andreasen C, Grøndahl MF, Deacon CF o.a. Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes? Diabetes, Obesity and Metabolism. 2018 aug;20(8):1937-1943. https://doi.org/10.1111/dom.13321

Author

Andersen, Emilie S. ; Lund, A. ; Bagger, J. I. ; Andreasen, C ; Grøndahl, MF ; Deacon, Carolyn F. ; Hartmann, Bolette ; Holst, Jens Juul ; Knop, Filip Krag ; Lauritsen, Tina Vilsbøll. / Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. I: Diabetes, Obesity and Metabolism. 2018 ; Bind 20, Nr. 8. s. 1937-1943.

Bibtex

@article{631116d895cf4875a4685b2fbc50d8bb,
title = "Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?",
author = "Andersen, {Emilie S.} and A. Lund and Bagger, {J. I.} and C Andreasen and MF Gr{\o}ndahl and Deacon, {Carolyn F.} and Bolette Hartmann and Holst, {Jens Juul} and Knop, {Filip Krag} and Lauritsen, {Tina Vilsb{\o}ll}",
year = "2018",
month = "8",
doi = "10.1111/dom.13321",
language = "English",
volume = "20",
pages = "1937--1943",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Is glucagon‐like peptide‐1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?

AU - Andersen, Emilie S.

AU - Lund, A.

AU - Bagger, J. I.

AU - Andreasen, C

AU - Grøndahl, MF

AU - Deacon, Carolyn F.

AU - Hartmann, Bolette

AU - Holst, Jens Juul

AU - Knop, Filip Krag

AU - Lauritsen, Tina Vilsbøll

PY - 2018/8

Y1 - 2018/8

U2 - 10.1111/dom.13321

DO - 10.1111/dom.13321

M3 - Journal article

C2 - 29654643

VL - 20

SP - 1937

EP - 1943

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 8

ER -

ID: 195511796